NYSE:PRGO - Perrigo Stock Price, Price Target & More

Perrigo trades on the New York Stock Exchange (NYSE) under the ticker symbol "PRGO."

Perrigo declared a quarterly dividend on Thursday, May 3rd. Shareholders of record on Friday, June 1st will be given a dividend of $0.19 per share on Tuesday, June 19th. This represents a $0.76 dividend on an annualized basis and a yield of 1.00%. The ex-dividend date is Thursday, May 31st. View Perrigo's Dividend History.

Perrigo Company PLC (NYSE:PRGO) released its quarterly earnings results on Tuesday, May, 8th. The company reported $1.26 EPS for the quarter, topping the consensus estimate of $1.14 by $0.12. The company had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.21 billion. Perrigo had a net margin of 2.59% and a return on equity of 11.93%. The company's revenue was up 1.9% compared to the same quarter last year. During the same period in the previous year, the company posted $1.05 EPS. View Perrigo's Earnings History.

Perrigo is scheduled to release their next quarterly earnings announcement on Thursday, August, 9th 2018. View Earnings Estimates for Perrigo.

Perrigo updated its FY18 earnings guidance on Tuesday, May, 8th. The company provided EPS guidance of $5.05-5.45 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.26.

17 analysts have issued 12 month price objectives for Perrigo's stock. Their forecasts range from $74.00 to $117.00. On average, they expect Perrigo's stock price to reach $93.3750 in the next year. This suggests a possible upside of 22.9% from the stock's current price. View Analyst Ratings for Perrigo.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Perrigo in the last year. There are currently 1 sell rating, 8 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

Some companies that are related to Perrigo include Zoetis (ZTS), Regeneron Pharmaceuticals (REGN), Takeda Pharmaceutical (TKPYY), ASTELLAS PHARMA/ADR (ALPMY), Alexion Pharmaceuticals (ALXN), Shiseido (SSDOY), Teva Pharmaceutical Industries (TEVA), Mylan (MYL), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), Ono Pharmaceutical (OPHLF), Alnylam Pharmaceuticals (ALNY) and Jazz Pharmaceuticals (JAZZ).

News headlines about PRGO stock have been trending somewhat positive recently, Accern reports. Accern ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Perrigo earned a media sentiment score of 0.07 on Accern's scale. They also assigned media coverage about the company an impact score of 45.33 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Perrigo's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Manning & Napier Group LLC (1.07%), Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management (0.22%), Bank of Montreal Can (0.13%), Fisher Asset Management LLC (0.07%), Retirement Systems of Alabama (0.04%) and Moon Capital Management LLC (0.03%). Company insiders that own Perrigo stock include Gary K Kunkle Jr, Geoffrey M Parker, Herman Morris Jr, Jeffrey C Smith, Jeffrey Needham, John Wesolowski, Judy L Brown, Sharon Kochan, Thomas Farrington, Todd W Kingma and Uwe Roehrhoff. View Institutional Ownership Trends for Perrigo.

PRGO stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Manning & Napier Group LLC, Bank of Montreal Can, Tokio Marine Asset Management Co. Ltd., Retirement Systems of Alabama, Fjarde AP Fonden Fourth Swedish National Pension Fund, Gateway Investment Advisers LLC and Gofen & Glossberg LLC IL. Company insiders that have sold Perrigo company stock in the last year include Jeffrey Needham, John Wesolowski, Sharon Kochan, Thomas Farrington and Todd W Kingma. View Insider Buying and Selling for Perrigo.

PRGO stock was bought by a variety of institutional investors in the last quarter, including Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management, State of Alaska Department of Revenue, Moon Capital Management LLC, Xact Kapitalforvaltning AB, Municipal Employees Retirement System of Michigan, Nisa Investment Advisors LLC and Stonebridge Capital Management Inc.. Company insiders that have bought Perrigo stock in the last two years include Geoffrey M Parker, Jeffrey C Smith, John Wesolowski and Uwe Roehrhoff. View Insider Buying and Selling for Perrigo.

Shares of PRGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PRGO stock can currently be purchased for approximately $75.97.

Perrigo has a market capitalization of $10.50 billion and generates $4.95 billion in revenue each year. The company earns $119.60 million in net income (profit) each year or $4.93 on an earnings per share basis. Perrigo employs 10,400 workers across the globe.

Perrigo's mailing address is TREASURY BUILDING LOWER GRAND CANAL STREET, DUBLIN L2, 49010. The company can be reached via phone at 353-1709-4000 or via email at [email protected]